ICaspase 9 Suicide Gene System

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2015 Jun 15

PMID 26072403

Citations 13

Authors

Xiaoou Zhou

Antonio Di Stasi

Malcolm K Brenner

Affiliations

Soon will be listed here.

Abstract

Although cellular therapies may be effective in cancer treatment, their potential for expansion, damage of normal organs, and malignant transformation is a source of concern. The ability to conditionally eliminate aberrant cells in vivo would ameliorate these concerns and broaden the application of cellular therapy. We devised an inducible T-cell safety switch that can be stably and efficiently expressed in human T cells without impairing phenotype, function, or antigen specificity. This system is based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization using a small-molecule drug. When exposed to a synthetic dimerizing drug, the inducible caspase 9 (iC9) becomes activated and leads to the rapid apoptosis of cells expressing this construct. We have demonstrated the clinical feasibility and efficacy of this approach after haploidentical hematopoietic stem cell transplant (haplo-HSCT). A single dose of a small-molecule drug (AP1903) eliminated more than 90 % of the modified T cells within 30 min after administration and symptoms resolved without recurrence. This system has the potential to broaden the clinical applications of cellular therapy.

Citing Articles

Clinical progress in the development of CAR T cells to treat malignant glioma.

Grewal E, Nahed B, Carter B, Gerstner E, Curry W, Maus M J Neurooncol. 2024; 171(3):571-579.

PMID: 39695004 DOI: 10.1007/s11060-024-04909-7.

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.

Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N bioRxiv. 2024; .

PMID: 39605384 PMC: 11601352. DOI: 10.1101/2024.11.13.623476.

An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety.

Chen K, Manoury-Battais S, Kanaya N, Vogiatzi I, Borges P, Kruize S J Clin Invest. 2024; 135(2.

PMID: 39560995 PMC: 11735097. DOI: 10.1172/JCI181143.

Synthetic Cells and Molecules in Cellular Immunotherapy.

Lin H, Li C, Zhang W, Wu B, Wang Y, Wang S Int J Biol Sci. 2024; 20(8):2833-2859.

PMID: 38904025 PMC: 11186374. DOI: 10.7150/ijbs.94346.

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma.

Giraudo M, Jackson Z, Das I, Abiona O, Wald D Pathog Immun. 2024; 9(1):1-17.

PMID: 38550613 PMC: 10972674. DOI: 10.20411/pai.v9i1.647.

References

Clackson T, Yang W, Rozamus L, Hatada M, Amara J, Rollins C . Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998; 95(18):10437-42. PMC: 27912. DOI: 10.1073/pnas.95.18.10437. View

Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M . Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood. 2007; 109(11):4698-707. DOI: 10.1182/blood-2006-05-023416. View

Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E . Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001; 97(1):63-72. DOI: 10.1182/blood.v97.1.63. View

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

Schreiber S . Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991; 251(4991):283-7. DOI: 10.1126/science.1702904. View

Boyum A . Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97:77-89. View

Straathof K, Pule M, Yotnda P, Dotti G, Vanin E, Brenner M . An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005; 105(11):4247-54. PMC: 1895037. DOI: 10.1182/blood-2004-11-4564. View

Di Stasi A, Tey S, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C . Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18):1673-83. PMC: 3236370. DOI: 10.1056/NEJMoa1106152. View

Montagna D, Yvon E, Calcaterra V, Comoli P, Locatelli F, Maccario R . Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999; 93(10):3550-7. View

10.

Garin M, Garrett E, Tiberghien P, Apperley J, Chalmers D, Melo J . Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood. 2001; 97(1):122-9. DOI: 10.1182/blood.v97.1.122. View

11.

Amrolia P, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder E . Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003; 102(6):2292-9. DOI: 10.1182/blood-2002-11-3516. View

12.

Ciceri F, Bonini C, Lupo Stanghellini M, Bondanza A, Traversari C, Salomoni M . Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009; 10(5):489-500. DOI: 10.1016/S1470-2045(09)70074-9. View

13.

Rooney C, Smith C, Ng C, Loftin S, Sixbey J, Gan Y . Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998; 92(5):1549-55. View

14.

Spencer D, Wandless T, Schreiber S, Crabtree G . Controlling signal transduction with synthetic ligands. Science. 1993; 262(5136):1019-24. DOI: 10.1126/science.7694365. View

15.

Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P . Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma. 1998; 30(5-6):525-37. DOI: 10.3109/10428199809057565. View

16.

Zhou X, Di Stasi A, Tey S, Krance R, Martinez C, Leung K . Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014; 123(25):3895-905. PMC: 4064331. DOI: 10.1182/blood-2014-01-551671. View

17.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

18.

Iuliucci J, Oliver S, Morley S, Ward C, Ward J, Dalgarno D . Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001; 41(8):870-9. DOI: 10.1177/00912700122010771. View

19.

Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G . Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002; 360(9327):130-7. DOI: 10.1016/S0140-6736(02)09413-8. View

20.

Clipstone N, Crabtree G . Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992; 357(6380):695-7. DOI: 10.1038/357695a0. View